지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
Bupropion-Induced Erythema Multiforme
Annals of Dermatology
2015 .01
Linear Psoriasis along Blaschko’s Lines
Annals of Dermatology
2017 .01
A Case of Segmental Vitiligo Along Blaschko’s Lines
Annals of Dermatology
2018 .01
Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
Annals of Dermatology
2015 .01
Role of Re-irradiation in Salvage Treatment of Glioblastoma Multiforme
Asian Pacific journal of cancer prevention : APJCP
2016 .01
전신을 침범한 급성 다형홍반 치험 1례
한방안이비인후피부과학회지
2023 .02
Chemoradiotherapy Alters Protein Expression in Glioblastoma Multiforme
Journal of Clinical Neurology
2020 .01
급성 편도선염에 의해 촉발된 다형홍반 환자 치험 1례
한방안이비인후피부과학회지
2015 .01
코로나바이러스감염증-19 (COVID-19) 백신 접종 후 재발한 대상포진 치험 1례
한방안이비인후피부과학회지
2021 .11
Treatment of Drug-Induced Erythema Multiforme: Case Report
Journal of Oral Medicine and Pain
2019 .12
Treatment of Stevens-Johnson syndrome
Oral Biology Research
2016 .01
Epidemiological Study on the Incidence of Herpes Zoster in Nearby Cheonan
The Korean Journal of Pain
2015 .01
Inflammatory Bowel Disease and the Risk of Herpes Zoster
Gut and Liver
2019 .01
Frequency of Herpes Zoster Recurrence in Central District of Korea
Annals of Dermatology
2017 .01
Population-Based Epidemiologic Study on Herpes Zoster in Korea: Seven-Year Nationwide Analysis from 2010 to 2016
Annals of Dermatology
2019 .01
Current scenario and future applicability of antivirals against herpes zoster
The Korean Journal of Pain
2023 .01
Primary Angiosarcoma of the Skin Presenting as Mild Erythema
Annals of Dermatology
2017 .01
The Risk of Atrial Fibrillation after Herpes Zoster
Journal of Korean Medical Science
2018 .01
Recurrence of herpes zoster in a young woman with IgG3 deficiency
Korean Journal of Anesthesiology
2015 .01
Occurrence of erythema multiforme following COVID-19 vaccination: a review
Clinical and Experimental Vaccine Research
2023 .04
0